Exact Mass: 449.1858
Exact Mass Matches: 449.1858
Found 500 metabolites which its exact mass value is equals to given mass value 449.1858
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Glisoxepide
Glisoxepide is one of the sulphonamide-derived oral antidiabetic drugs. It inhibits the uptake of bile acids into isolated rat hepatocytes. However it inhibits taurocholate uptake only in the absence of sodium ions. Glisoxepide uptake could be further inhibited by blockers of the hepatocellular monocarboxylate transporter, by the loop diuretic bumetanide, by 4,4-diisothiocyano-2,2-stilbenedisulfonate (DIDS) and by sulphate. These results are consistent with the transport of glisoxepide via the transport system for the unconjugated bile acid cholate. (PMID:1618280, 9017793). A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BB - Sulfonylureas C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C97936 - Sulfonylurea Antidiabetic Agent
Ethyl n-allyl-n-[(e)-2-methyl-3-[4-(4-amidinophenoxycarbonyl)-phenyl]propenoyl]amino acetate
Iberdomide
N-Ethyl-N-(6,6-dimethyl-2-hepten-4-ynyl)-3-((3,3'-bithiophen-5-yl)methoxy)benzenemethanamine
N-[2,6-Bis(1-methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]urea
dihydrogeranylgeranyl-PP
Dihydrogeranylgeranyl-pp is practically insoluble (in water) and a moderately acidic compound (based on its pKa). Dihydrogeranylgeranyl-pp can be found in a number of food items such as chives, nanking cherry, muscadine grape, and towel gourd, which makes dihydrogeranylgeranyl-pp a potential biomarker for the consumption of these food products.
4-[[4-[Hydroxy(4-methoxyphenyl)methyl]-5-[(4-hydroxyphenyl)methyl]-1-methyl-1H-imidazol-2-yl]amino]-1-methyl-1H-imidazole-2,5-dione
Ser Thr Asn Glu
Ala Ala Cys Trp
Ala Ala Trp Cys
Ala Cys Ala Trp
Ala Cys Glu Lys
Ala Cys Lys Glu
Ala Cys Trp Ala
Ala Glu Cys Lys
Ala Glu Lys Cys
Ala Lys Cys Glu
Ala Lys Glu Cys
Ala Met Gln Thr
Ala Met Thr Gln
Ala Gln Met Thr
Ala Gln Thr Met
Ala Ser Ser Trp
Ala Ser Trp Ser
Ala Thr Met Gln
Ala Thr Gln Met
Ala Trp Ala Cys
Ala Trp Cys Ala
Ala Trp Ser Ser
Cys Ala Ala Trp
Cys Ala Glu Lys
Cys Ala Lys Glu
Cys Ala Trp Ala
Cys Cys Lys Pro
Cys Cys Pro Lys
Cys Glu Ala Lys
Cys Glu Lys Ala
Cys Ile Asn Thr
Cys Ile Gln Ser
Cys Ile Ser Gln
Cys Ile Thr Asn
Cys Lys Ala Glu
Cys Lys Cys Pro
Cys Lys Glu Ala
Cys Lys Pro Cys
Cys Leu Asn Thr
Cys Leu Gln Ser
Cys Leu Ser Gln
Cys Leu Thr Asn
Cys Asn Ile Thr
Cys Asn Leu Thr
Cys Asn Thr Ile
Cys Asn Thr Leu
Cys Pro Cys Lys
Cys Pro Lys Cys
Cys Gln Ile Ser
Cys Gln Leu Ser
Cys Gln Ser Ile
Cys Gln Ser Leu
Cys Gln Thr Val
Cys Gln Val Thr
Cys Ser Ile Gln
Cys Ser Leu Gln
Cys Ser Gln Ile
Cys Ser Gln Leu
Cys Thr Ile Asn
Cys Thr Leu Asn
Cys Thr Asn Ile
Cys Thr Asn Leu
Cys Thr Gln Val
Cys Thr Val Gln
Cys Val Gln Thr
Cys Val Thr Gln
Cys Trp Ala Ala
Asp Cys Arg Gly
Asp Gly Cys Arg
Asp Gly Lys Met
Asp Gly Met Lys
Asp Gly Arg Cys
Asp Lys Gly Met
Asp Lys Met Gly
Asp Met Gly Lys
Asp Met Lys Gly
Asp Asn Thr Thr
Asp Gln Ser Thr
Asp Gln Thr Ser
Asp Arg Cys Gly
Asp Arg Gly Cys
Asp Ser Gln Thr
Asp Ser Thr Gln
Asp Thr Asn Thr
Asp Thr Gln Ser
Asp Thr Ser Gln
Asp Thr Thr Asn
Glu Ala Cys Lys
Glu Ala Lys Cys
Glu Cys Ala Lys
Glu Cys Lys Ala
Glu Lys Ala Cys
Glu Lys Cys Ala
Glu Asn Ser Thr
Glu Asn Thr Ser
Glu Gln Ser Ser
Glu Ser Asn Thr
Glu Ser Gln Ser
Glu Ser Ser Gln
Glu Ser Thr Asn
Glu Thr Asn Ser
Glu Thr Ser Asn
Gly Cys Asp Arg
Gly Cys Arg Asp
Gly Asp Cys Arg
Gly Asp Lys Met
Gly Asp Met Lys
Gly Asp Arg Cys
Gly Gly Met Trp
Gly Gly Trp Met
Gly Lys Asp Met
Gly Lys Met Asp
Gly Met Asp Lys
Gly Met Gly Trp
Gly Met Lys Asp
Gly Met Trp Gly
Gly Asn Pro Tyr
Gly Asn Tyr Pro
Gly Pro Asn Tyr
Gly Pro Tyr Asn
Gly Arg Cys Asp
Gly Arg Asp Cys
Gly Ser Thr Trp
Gly Ser Trp Thr
Gly Thr Ser Trp
Gly Thr Trp Ser
Gly Trp Gly Met
Gly Trp Met Gly
Gly Trp Ser Thr
Gly Trp Thr Ser
Gly Tyr Asn Pro
Gly Tyr Pro Asn
Ile Cys Asn Thr
Ile Cys Gln Ser
Ile Cys Ser Gln
Ile Cys Thr Asn
Ile Asn Cys Thr
Ile Asn Thr Cys
Ile Gln Cys Ser
Ile Gln Ser Cys
Ile Ser Cys Gln
Ile Ser Gln Cys
Ile Thr Cys Asn
Ile Thr Asn Cys
Lys Ala Cys Glu
Lys Ala Glu Cys
Lys Cys Ala Glu
Lys Cys Cys Pro
Lys Cys Glu Ala
Lys Cys Pro Cys
Lys Asp Gly Met
Lys Asp Met Gly
Lys Glu Ala Cys
Lys Glu Cys Ala
Lys Gly Asp Met
Lys Gly Met Asp
Lys Met Asp Gly
Lys Met Gly Asp
Lys Pro Cys Cys
Leu Cys Asn Thr
Leu Cys Gln Ser
Leu Cys Ser Gln
Leu Cys Thr Asn
Leu Asn Cys Thr
Leu Asn Thr Cys
Leu Gln Cys Ser
Leu Gln Ser Cys
Leu Ser Cys Gln
Leu Ser Gln Cys
Leu Thr Cys Asn
Leu Thr Asn Cys
Met Ala Gln Thr
Met Ala Thr Gln
Met Asp Gly Lys
Met Asp Lys Gly
Met Gly Asp Lys
Met Gly Gly Trp
Met Gly Lys Asp
Met Gly Trp Gly
Met Lys Asp Gly
Met Lys Gly Asp
Met Asn Ser Val
Met Asn Val Ser
Met Gln Ala Thr
Met Gln Thr Ala
Met Ser Asn Val
Met Ser Val Asn
Met Thr Ala Gln
Met Thr Gln Ala
Met Val Asn Ser
Met Val Ser Asn
Met Trp Gly Gly
Asn Cys Ile Thr
Asn Cys Leu Thr
Asn Cys Thr Ile
Asn Cys Thr Leu
Asn Asp Thr Thr
Asn Glu Ser Thr
Asn Glu Thr Ser
Asn Gly Pro Tyr
Asn Gly Tyr Pro
Asn Ile Cys Thr
Asn Ile Thr Cys
Asn Leu Cys Thr
Asn Leu Thr Cys
Asn Met Ser Val
Asn Met Val Ser
Asn Pro Gly Tyr
Asn Pro Tyr Gly
Asn Ser Glu Thr
Asn Ser Met Val
Asn Ser Thr Glu
Asn Ser Val Met
Asn Thr Cys Ile
Asn Thr Cys Leu
Asn Thr Asp Thr
Asn Thr Glu Ser
Asn Thr Ile Cys
Asn Thr Leu Cys
Asn Thr Ser Glu
Asn Thr Thr Asp
Asn Val Met Ser
Asn Val Ser Met
Asn Tyr Gly Pro
Asn Tyr Pro Gly
Pro Cys Cys Lys
Pro Cys Lys Cys
Pro Gly Asn Tyr
Pro Gly Tyr Asn
Pro Lys Cys Cys
Pro Asn Gly Tyr
Pro Asn Tyr Gly
Pro Tyr Gly Asn
Pro Tyr Asn Gly
Gln Ala Met Thr
Gln Ala Thr Met
Gln Cys Ile Ser
Gln Cys Leu Ser
Gln Cys Ser Ile
Gln Cys Ser Leu
Gln Cys Thr Val
Gln Cys Val Thr
Gln Asp Ser Thr
Gln Asp Thr Ser
Gln Glu Ser Ser
Gln Ile Cys Ser
Gln Ile Ser Cys
Gln Leu Cys Ser
Gln Leu Ser Cys
Gln Met Ala Thr
Gln Met Thr Ala
Gln Ser Cys Ile
Gln Ser Cys Leu
Gln Ser Asp Thr
Gln Ser Glu Ser
Gln Ser Ile Cys
Gln Ser Leu Cys
Gln Ser Ser Glu
Gln Ser Thr Asp
Gln Thr Ala Met
Gln Thr Cys Val
Gln Thr Asp Ser
Gln Thr Met Ala
Gln Thr Ser Asp
Gln Thr Val Cys
Gln Val Cys Thr
Gln Val Thr Cys
Arg Cys Asp Gly
Arg Asp Cys Gly
Arg Asp Gly Cys
Arg Gly Cys Asp
Arg Gly Asp Cys
Ser Ala Ser Trp
Ser Ala Trp Ser
Ser Cys Ile Gln
Ser Cys Leu Gln
Ser Cys Gln Ile
Ser Cys Gln Leu
Ser Asp Gln Thr
Ser Asp Thr Gln
Ser Glu Asn Thr
Ser Glu Gln Ser
Ser Glu Ser Gln
Ser Glu Thr Asn
Ser Gly Thr Trp
Ser Gly Trp Thr
Ser Ile Cys Gln
Ser Ile Gln Cys
Ser Leu Cys Gln
Ser Leu Gln Cys
Ser Met Asn Val
Ser Met Val Asn
Ser Asn Glu Thr
Ser Asn Met Val
Ser Asn Thr Glu
Ser Asn Val Met
Ser Gln Cys Ile
Ser Gln Cys Leu
Ser Gln Asp Thr
Ser Gln Glu Ser
Ser Gln Ile Cys
Ser Gln Leu Cys
Ser Gln Ser Glu
Ser Gln Thr Asp
Ser Ser Ala Trp
Ser Ser Glu Gln
Ser Ser Gln Glu
Ser Ser Trp Ala
Ser Thr Asp Gln
Ser Thr Glu Asn
Ser Thr Gly Trp
Ser Thr Gln Asp
Ser Thr Trp Gly
Ser Val Met Asn
Ser Val Asn Met
Ser Trp Ala Ser
Ser Trp Gly Thr
Ser Trp Ser Ala
Ser Trp Thr Gly
Thr Ala Met Gln
Thr Ala Gln Met
Thr Cys Ile Asn
Thr Cys Leu Asn
Thr Cys Asn Ile
Thr Cys Asn Leu
Thr Cys Gln Val
Thr Cys Val Gln
Thr Asp Asn Thr
Thr Asp Gln Ser
Thr Asp Ser Gln
Thr Asp Thr Asn
Thr Glu Asn Ser
Thr Glu Ser Asn
Thr Gly Ser Trp
Thr Gly Trp Ser
Thr Ile Cys Asn
Thr Ile Asn Cys
Thr Leu Cys Asn
Thr Leu Asn Cys
Thr Met Ala Gln
Thr Met Gln Ala
Thr Asn Cys Ile
Thr Asn Cys Leu
Thr Asn Asp Thr
Thr Asn Glu Ser
Thr Asn Ile Cys
Thr Asn Leu Cys
Thr Asn Ser Glu
Thr Asn Thr Asp
Thr Gln Ala Met
Thr Gln Cys Val
Thr Gln Asp Ser
Thr Gln Met Ala
Thr Gln Ser Asp
Thr Gln Val Cys
Thr Ser Asp Gln
Thr Ser Glu Asn
Thr Ser Gly Trp
Thr Ser Asn Glu
Thr Ser Gln Asp
Thr Ser Trp Gly
Thr Thr Asp Asn
Thr Thr Asn Asp
Thr Val Cys Gln
Thr Val Gln Cys
Thr Trp Gly Ser
Thr Trp Ser Gly
Val Cys Gln Thr
Val Cys Thr Gln
Val Met Asn Ser
Val Met Ser Asn
Val Asn Met Ser
Val Asn Ser Met
Val Gln Cys Thr
Val Gln Thr Cys
Val Ser Met Asn
Val Ser Asn Met
Val Thr Cys Gln
Val Thr Gln Cys
Trp Ala Ala Cys
Trp Ala Cys Ala
Trp Ala Ser Ser
Trp Cys Ala Ala
Trp Gly Gly Met
Trp Gly Met Gly
Trp Gly Ser Thr
Trp Gly Thr Ser
Trp Met Gly Gly
Trp Ser Ala Ser
Trp Ser Gly Thr
Trp Ser Ser Ala
Trp Ser Thr Gly
Trp Thr Gly Ser
Trp Thr Ser Gly
Tyr Gly Asn Pro
Tyr Gly Pro Asn
Tyr Asn Gly Pro
Tyr Asn Pro Gly
Tyr Pro Gly Asn
Tyr Pro Asn Gly
Glisoxepid
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BB - Sulfonylureas C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C97936 - Sulfonylurea Antidiabetic Agent
(3R,5S,6E)-rel-7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-Heptenoic acid ethyl ester
ETHYL [R-(R*,S*)]-3,5-DIHYDROXY-7-[2-CYCLOPROPYL-4-(4-FLUOROPHENYL)-3-QUINOLINYL]-HEPT-6-ENOATE
4-[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]-2,2-diphenyl-butyric acid
3-Pyridinecarboxylic acid, 4-[4-fluoro-2-(phenylmethoxy)phenyl]-5-formyl-2,6-bis(1-methylethyl)-, methyl ester
(E)-N-ethyl-6,6-dimethyl-N-[[3-[(4-thiophen-3-ylthiophen-2-yl)methoxy]phenyl]methyl]hept-2-en-4-yn-1-amine
NB-598 is a potent and competitive inhibitor of squalene epoxidase (SE), and suppresses triglyceride biosynthesis through the farnesol pathway. NB-598 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
N-[2,6-Bis(1-methylethyl)phenyl]-N-[4-[(4-nitrophenyl)thio]phenyl]urea
VULM 1457 is a potent inhibitor of cholesterol acyltransferase (acyl-CoA). VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM 1457 has the potential for the research of diabetes mellitus and hypercholesterolaemia[1][2].
(4-carbamimidoylphenyl) 4-[(E)-3-[(2-ethoxy-2-oxoethyl)-prop-2-enylamino]-2-methyl-3-oxoprop-1-enyl]benzoate
2-[[2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl]methylsulfinyl]-N-[3-(1-pyrrolidinyl)propyl]acetamide
N-[[4-[oxo-[4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]methyl]benzenesulfonamide
[4-(2,5-Diphenyl-7-pyrazolo[1,5-a]pyrimidinyl)-1-piperazinyl]-(3-furanyl)methanone
trans-4-[({2-[(2-oxo-3-phenyl-2H-chromen-7-yl)oxy]propanoyl}amino)methyl]cyclohexanecarboxylic acid
N-[3-(3,5-dimethyl-1-pyrazolyl)-2-hydroxypropyl]-N-(4-methylphenyl)-2-naphthalenesulfonamide
(E)-2-Cyano-3-(2-dibenzylamino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl)-N-methyl-acrylamide
3-[4-[(E,3E)-3-(1,3,3-trimethylindol-2-ylidene)prop-1-enyl]quinolin-1-ium-1-yl]propane-1-sulfonic acid
(1S,9R,10R,11R)-10-(hydroxymethyl)-6-oxo-N-[(1R)-1-phenylethyl]-12-(3,3,3-trifluoropropyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1S,9R,10R,11R)-5-(cyclohexen-1-yl)-10-(hydroxymethyl)-6-oxo-12-(2-pyridin-2-ylacetyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylic acid
(2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-1-[1-oxo-2-(3-pyridinyl)ethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester
(2S,3S,3aR,9bR)-7-(2-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-(pyridin-4-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester
methyl (2S,3S,3aR,9bR)-1-[(3-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-7-pyridin-3-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylate
(1R,9S,10S,11S)-10-(hydroxymethyl)-6-oxo-N-[(1R)-1-phenylethyl]-12-(3,3,3-trifluoropropyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1R,9S,10S,11S)-5-(cyclohexen-1-yl)-10-(hydroxymethyl)-6-oxo-12-(2-pyridin-2-ylacetyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylic acid
methyl (2R,3R,3aS,9bS)-7-(cyclopenten-1-yl)-3-(hydroxymethyl)-6-oxo-1-(2-pyridin-3-ylacetyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylate
(1S,9R,10R,11R)-N-ethyl-10-(hydroxymethyl)-6-oxo-5-phenyl-12-(3,3,3-trifluoropropyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
methyl (1R,9S,10S,11S)-5-(4-fluorophenyl)-10-(hydroxymethyl)-6-oxo-12-(pyridin-3-ylmethyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylate
(1S,9R,10R,11R)-10-(hydroxymethyl)-6-oxo-N-[(1S)-1-phenylethyl]-12-(3,3,3-trifluoropropyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1R,9S,10S,11S)-N-ethyl-10-(hydroxymethyl)-6-oxo-5-phenyl-12-(3,3,3-trifluoropropyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
methyl (1S,9R,10R,11R)-5-(4-fluorophenyl)-10-(hydroxymethyl)-6-oxo-12-(pyridin-3-ylmethyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylate
(2S,3S,3aR,9bR)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-7-phenyl-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
[(1S)-7-methoxy-2-methylsulfonyl-1-(4-oxanylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
(1R,9S,10S,11S)-10-(hydroxymethyl)-6-oxo-N-[(1S)-1-phenylethyl]-12-(3,3,3-trifluoropropyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(2R,3R,3aS,9bS)-7-(2-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-(pyridin-4-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester
(2R,3R,3aS,9bS)-1-[(3-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-7-(3-pyridinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester
(2R,3R,3aS,9bS)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-7-phenyl-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
[(1R)-7-methoxy-2-methylsulfonyl-1-(4-oxanylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
NP10679
NP10679 is a selective, pH dependent GluN2B subunit-specific N-methyl-D-aspartate (NMDA) receptor inhibitor with high oral bioavailability and good brain penetration. NP10679 inhibits GluN2B with IC50s of 23 and 142 nM at pH 6.9 and 7.6, respectively. NP10679 is a histamine H1 antagonist and a hERG channel inhibitor with IC50s of 73 and 620 nM, respectively. NP10679 is a reversible inhibitor of human liver CYP enzymes[1].